<![CDATA[삼성바이오에피스 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=26146>Sat, 02 May 2026 13:56:30 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Samsung Bioepis Announces US Launch of ONTRUZANT® (trastuzumab-dttb) for Early and Metastatic HER2-overexpressing Breast Cancer and Metastatic Gastric Cancer]]>https://www.newswire.co.kr/newsRead.php?no=903783Thu, 16 Apr 2020 09:25:41 +0900<![CDATA[Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates]]>https://www.newswire.co.kr/newsRead.php?no=896888Thu, 07 Nov 2019 15:48:19 +0900<![CDATA[Samsung Bioepis Presents Real-world Data of BENEPALI™ (etanercept) in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress]]>https://www.newswire.co.kr/newsRead.php?no=895333Thu, 10 Oct 2019 10:48:24 +0900<![CDATA[Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar Candidate, at the European Society for Medical Oncology (ESMO) 2019 Congress]]>https://www.newswire.co.kr/newsRead.php?no=894742Fri, 27 Sep 2019 11:13:07 +0900<![CDATA[Samsung Bioepis' Marketing Authorization Application for SB3 Trastuzumab Biosimilar Candidate Accepted for Review by the European Medicines Agency]]>https://www.newswire.co.kr/newsRead.php?no=836536Tue, 04 Oct 2016 11:45:00 +0900<![CDATA[Samsung Bioepis' SB4 (BRENZYS™) Becomes First Etanercept Biosimilar to Receive Regulatory Approval in Canada]]>https://www.newswire.co.kr/newsRead.php?no=835280Tue, 13 Sep 2016 11:25:00 +0900<![CDATA[Samsung Bioepis' Marketing Authorization Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the European Medicines Agency]]>https://www.newswire.co.kr/newsRead.php?no=831221Mon, 18 Jul 2016 11:15:00 +0900<![CDATA[Samsung Bioepis Announces New Data on Three Anti-TNF-α Biosimilar Molecules at the Annual European Congress on Rheumatology (EULAR 2016)]]>https://www.newswire.co.kr/newsRead.php?no=828186Thu, 09 Jun 2016 09:15:00 +0900<![CDATA[Samsung Bioepis Becomes First to Obtain European Commission Approval for Second Anti-TNF-α Biosimilar with Flixabi®]]>https://www.newswire.co.kr/newsRead.php?no=827380Mon, 30 May 2016 13:55:00 +0900<![CDATA[Samsung Bioepis' Biologics License Application for SB2 Infliximab Biosimilar Accepted by U.S. Food and Drug Administration]]>https://www.newswire.co.kr/newsRead.php?no=826810Tue, 24 May 2016 10:10:00 +0900<![CDATA[Samsung Bioepis' Flixabi® Infliximab Biosimilar Recommended for Approval in the European Union]]>https://www.newswire.co.kr/newsRead.php?no=822184Mon, 04 Apr 2016 09:00:00 +0900<![CDATA[Samsung Bioepis Enters the European Biopharmaceutical Market with Benepali®, the First Fusion Protein Biosimilar Approved by the European Commission]]>https://www.newswire.co.kr/newsRead.php?no=815346Mon, 18 Jan 2016 09:20:00 +0900<![CDATA[Samsung Bioepis' RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea]]>https://www.newswire.co.kr/newsRead.php?no=811823Mon, 07 Dec 2015 09:30:00 +0900<![CDATA[Samsung Bioepis Receives Positive CHMP Opinion for the First Etanercept Biosimilar in the European Union]]>https://www.newswire.co.kr/newsRead.php?no=810426Mon, 23 Nov 2015 10:15:00 +0900